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Abstract
Background: Efavirenz is a commonly prescribed antiretroviral drug that is largely well tolerated. However, seizure
disorder is a rare side effect. Prompt identification and immediate replacement of efavirenz with an alternative drug
would effectively stop the seizures. To the best of our knowledge, we present the first reported case in the
literature of complex partial seizures arising due to efavirenz.
Case presentation: We report a case of a 33-year-old Nigerian man treated with an efavirenz-based antiretroviral
regimen for human immunodeficiency virus infection. He presented with seizures soon after commencement of
antiretroviral drugs. His magnetic resonance imaging results were unremarkable. His blood levels of sodium,
glucose, urea, and creatinine were within normal limits. However, his electroencephalogram showed intermittent
bursts of high-voltage sharp waves and spikes bilaterally over frontotemporoparietal regions, a finding consistent
with complex partial seizures. His efavirenz plasma level was 209.55 μg/ml. His seizures stopped following a switch
to a non-efavirenz-based regimen.
Conclusions: This report brings to light the occurrence of complex partial seizures in patients on efavirenz. It also
demonstrates the effective resolution of seizures when efavirenz treatment is replaced with a non-efavirenz-based
regimen.
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Background
The 2010 global estimate of persons living with HIV was
33.4 million, with about 22.5 million (67 %) living in sub-
Saharan Africa [1]. Highly active antiretroviral therapy
(HAART) is essential in the reduction of morbidity and
mortality related to HIV infection. It improves the quality of
life and life expectancy of individuals with HIV infection.
HAART results in sustained suppression of plasma HIV
viral load and a significant improvement in immune status
as measured by absolute and percentage cluster of differenti-
ation 4-positive (CD4+) counts [2, 3]. Efavirenz is a com-
monly prescribed antiretroviral drug.
Although adherence to antiretroviral drug therapies is
invaluable in the successful management of patients with
HIV [4], adverse drug reactions are a major factor militat-
ing against use of these drugs [5]. Efavirenz frequently
causes central nervous system (CNS) symptoms such as
dizziness and hallucinations [6]; it can also precipitate
psychosis, especially in patients with a previous history of
psychiatric illness [7]. Seizure disorder is a documented
side effect of efavirenz [8]. There are some case reports of
efavirenz causing various types of seizure disorders, such
as status epilepticus and absence seizures [8, 9].
Case presentation
A 33-year-old Nigerian man who presented with HIV in-
fection was commenced on HAART (tenofovir 300 mg,
emtricitabine 200 mg, and efavirenz 600 mg) for about
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1 month and then developed generalized tonic-clonic
seizures that occurred once in 3 months. He had no pre-
ceding history of seizures or family history of seizures,
nor did he have any history suggestive of CNS infection
or any use of psychotropic drugs or other form of drug
treatment.
His clinical examination results were normal. His
blood pressure was 120/80 mmHg; his baseline CD4
count was 130 cells/mm3; his blood sodium and
glucose levels were normal at 137 mmol/L and
5.5 mmol/L, respectively; and his urea and creatinine
were also within normal limits. Although his magnetic
resonance imaging findings were unremarkable, an
electroencephalogram showed intermittent bursts of
high-voltage sharp waves and spikes bilaterally over
frontotemporoparietal regions, consistent with com-
plex partial seizures (Fig. 1). The patient was initially
administered sodium valproate with no appreciable
control of seizures. His efavirenz plasma level was
measured using high-performance liquid chromatog-
raphy and was found to be 209.55 μg/ml. Efavirenz
was subsequently replaced with nevirapine, resulting
in instant resolution of his seizures. He has been seiz-
ure free for 3 years and has not required the use of
any anticonvulsant. A repeat electroencephalogram
showed no sign of seizure activity (Fig. 2).
Discussion
Efavirenz readily crosses the blood-brain barrier owing to
its lipophilic nature. It attains a therapeutic concentration
in the cerebrospinal fluid that is about 0.5–1.2 % of its
corresponding plasma level [10]. Over 50 % of individuals
initiated on an efavirenz-based regimen complain of CNS-
related side effects. However, these side effects are usually
mild and resolve within 1 month of initiating therapy. A
rare but well-documented adverse effect of efavirenz is seiz-
ure disorder. Our patient showed evidence of complex
partial seizures that persisted despite intervention with an
antiepileptic drug (sodium valproate). His seizures resolved
following replacement of efavirenz with nevirapine in the
antiretroviral regimen.
Measurement of our patient’s efavirenz plasma concen-
tration revealed an extremely high value of 209.55 μg/ml
(normal range 1–4 μg/ml) [11]. Conflicting findings have
Fig. 1 Electroencephalogram of the patient with human immunodeficiency virus while on efavirenz, showing complex partial seizures, October 2011
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been reported regarding the association between efavirenz
plasma levels and neuropsychiatric adverse events.
Researchers in some studies have reported that higher efa-
virenz concentration predisposes patients to CNS toxicity
[6, 12], whereas others have reported no relationship at all
[14]. The abnormal level of efavirenz observed in our pa-
tient may have been due to racial differences in the metab-
olism of the drug. Patients of African origin tend to have
more cytochrome P2B6 (CYP2B6) G516T and CYP2B6
T516T genotypes than their white counterparts and are
regarded as poor metabolizers of efavirenz [12, 13]. People
who are homozygous for the CYP2B6 516T/T genotype,
which is associated with poor efavirenz clearance, are more
at risk of efavirenz-induced seizure disorder. The half-life of
efavirenz is 40–55 h; in addition, efavirenz is highly protein
bound and may be associated with increased adverse ef-
fects, including CNS toxicity, especially when taken with
food because of increased absorption [14]. The mechanism
of efavirenz-induced seizure disorder is unknown; however,
it may be a direct epileptogenic effect, especially at high
doses or with poor drug clearance and drug-drug inter-
action [6]. The limitations of our present case are our
inability to determine the patient’s cytochrome P450 geno-
type and that his blood calcium and magnesium levels were
not measured.
Conclusions
This report presents information regarding the occur-
rence of complex partial seizures in patients receiving
efavirenz treatment. It also demonstrably posits that re-
placing the culpable antiretroviral drug with a non-
efavirenz-based regimen can be extremely effective.
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